Astrazeneca (NYSE:AZN) Posts Earnings Results, Beats Expectations By $0.07 EPS

Astrazeneca (NYSE:AZN) released its earnings results on Wednesday. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.07, FiscalAI reports. Astrazeneca had a net margin of 17.19% and a return on equity of 31.01%. The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.98 billion.

Here are the key takeaways from Astrazeneca’s conference call:

• Q1 showed solid commercial momentum with total revenue +8%, core operating profit +12% and core EPS +5%, and management reiterated full-year guidance (mid-to-high single?digit revenue growth; low double?digit core EPS growth at CER).
• Management highlighted strong pipeline execution — 14 approvals since Q4 2025 and four positive Phase III readouts in Q1 (including two NMEs, Tozorakimab and eplontersen) — saying the portfolio of upcoming catalysts implies a risk?adjusted peak?year revenue potential exceeding $10 billion.
• Tozorakimab reported statistically significant, clinically meaningful reductions in moderate?to?severe COPD exacerbations in OBERON and TITANIA (MIRANDA also positive), was well tolerated, and the company expects a broad label across eosinophil levels with a peak?sales view of ~$3–5 billion.
• BioPharmaceuticals revenue was broadly stable overall but CVRM fell 6% as Farxiga faced phased loss?of?exclusivity and China VBP headwinds (U.S. generic entry in April); management is betting on upcoming launches (eg, Baxdrostat PDUFA Q2) to offset near?term LOE pressure.
• Balance?sheet and cashflow notes: CapEx is rising (~33% in 2026) for manufacturing investments, milestone/deal payments of about $2.5 billion are expected this year, net debt increased ~$2.5 billion in Q1, and the company reiterated that forward?looking statements carry risks and uncertainties.

Astrazeneca Price Performance

Shares of AZN stock traded down $2.11 during trading hours on Friday, hitting $185.26. The stock had a trading volume of 1,282,245 shares, compared to its average volume of 2,769,641. The company has a market capitalization of $287.32 billion, a P/E ratio of 31.34, a PEG ratio of 1.40 and a beta of 0.35. Astrazeneca has a twelve month low of $132.32 and a twelve month high of $212.71. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51.

Astrazeneca Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio is currently 73.43%.

Wall Street Analyst Weigh In

AZN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Thursday. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Thursday. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research note on Thursday, April 23rd. Finally, Citigroup initiated coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.67.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Barclays upgraded AZN from “neutral” to “buy”, signaling upward analyst momentum that could support the stock. Barclays Upgrade
• Positive Sentiment: DZ Bank also moved to “buy”, adding to the wave of bullish analyst sentiment after Q1 results. DZ Bank Upgrade
• Positive Sentiment: Citi raised its 2026 core EPS forecast and kept a “buy” rating, citing under?priced late?year pipeline readouts — a catalyst horizon investors should monitor. Citi Note
• Positive Sentiment: Small?cap partner Pinetree announced AZN exercised an option to license PTX?299 (EGFR degrader), triggering a $25M payment — an immediate cash outflow for Pinetree and a strategic expansion of AZN’s oncology pipeline. Pinetree Option Exercise
• Neutral Sentiment: ODAC delivered a split decision overall — it backed an AstraZeneca prostate?cancer regimen while rejecting camizestrant for a breast cancer indication, creating a mixed outlook across the oncology portfolio. Benzinga: Mixed ODAC
• Neutral Sentiment: Analyst bulls (e.g., 24/7 Wall St.) point to >20 Phase III readouts and the company’s Q1 beat/reaffirmed guidance as upside catalysts — these are medium?term drivers rather than immediate relief. 24/7 Wall St. Outlook
• Negative Sentiment: The FDA Oncologic Drugs Advisory Committee voted 6?3 against recommending camizestrant in combination with a CDK4/6 inhibitor for first?line advanced HR+ breast cancer, citing trial?design and benefit?risk concerns — the principal driver of the intraday weakness. Reuters: ODAC Vote
• Negative Sentiment: Deutsche Bank reaffirmed a “sell” rating, providing countervailing pressure amid the analyst upgrade headlines. Deutsche Bank Reaffirm
• Negative Sentiment: Erste Group trimmed its FY2026 EPS forecast slightly, a reminder some brokers are revising near?term estimates despite the Q1 beat. (Analyst note issued April 27)

Institutional Investors Weigh In On Astrazeneca

Several large investors have recently modified their holdings of AZN. Brighton Jones LLC boosted its holdings in shares of Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after acquiring an additional 2,789 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after acquiring an additional 11,690 shares during the period. Amundi boosted its holdings in shares of Astrazeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after acquiring an additional 3,618 shares during the period. Jump Financial LLC boosted its holdings in shares of Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after acquiring an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after acquiring an additional 559 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.